Covered Versus Uncovered Self-expandable Metallic Stents for Malignant Gastric Outlet Obstruction
NCT01646476 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 102
Last updated 2017-03-01
Summary
Malignant gastric outlet obstruction can result from gastric adenocarcinoma, leading to intractable vomiting, nausea, and poor oral food intake. Although self-expandable metallic stent (SEMS) insertion has excellent technical and clinical success rates for relieving gastric outlet obstruction symptoms, the uncovered SEMS is susceptible to re-stenosis because of tumor ingrowth through openings between the stent wire filaments. Therefore, the most common reason for stent failure in uncovered stents is tumor ingrowth.
The covered SEMS has a membrane that prevents ingrowth through the mesh wall and consequently shows lower rate of re-stenosis than uncovered SEMS. However, covered SEMS has a higher risk of stent migration compared to uncovered SEMS. Recent prospective, randomized study showed that there was no significant difference between uncovered and covered SEMS in terms of stent patency rate as well as technical and clinical success rates.
Recently the investigators developed new covered SEMS for gastric outlet obstruction. This new covered SEMS has features that may contribute to reducing migration rate: 1) partially covered design; 2)less radial force in central portion of stent; 3) presence of lasso which enable position of stent to be adjusted after deployment; 4)presence of protrusion in both sides of stent. This prospective, randomized study aimed to compare the effectiveness and side effects of newly developed covered SEMS with those of uncovered SEMS in patients with malignant gastric outlet obstruction from gastric cancer.
Conditions
- Gastric Outlet Obstruction Due to Gastric Adenocarcinoma
Interventions
- DEVICE
-
Covered stent (Bona stent pyloric/duodenal covered) insertion
self-expandable metallic stent placement was performed with a therapeutic endoscope (working channel ≥ 3.7 mm) using a through-the-scope method. All patients underwent procedures under conscious sedation with midazolam and pethidine. The length of the stricture was assessed either endoscopically or fluoroscopically; the length of the stent had to exceed that of the stricture by at least 3 cm. After the required stent length was determined, the stent was advanced through the endoscope over a guidewire until it passed across the distal end of the stricture. Then, the stent was deployed under continuous fluoroscopic control. For the Wave covered stent group, the stent was repositioned after deployment using the lasso under fluoroscopic guidance (if necessary), aligning the central portion of the stricture with the central portion of the stent which had reduced radial force and indentation. Stent positioning was confirmed endoscopically and fluoroscopically.
- DEVICE
-
Uncovered stent (Bona stent, pyloric/duodenal) insertion
Self-expandable metallic stent placement was performed with a therapeutic endoscope (working channel ≥ 3.7 mm) using a through-the-scope method. All patients underwent procedures under conscious sedation with midazolam and pethidine. The length of the stricture was assessed either endoscopically or fluoroscopically; the length of the stent had to exceed that of the stricture by at least 3 cm. After the required stent length was determined, the stent was advanced through the endoscope over a guidewire until it passed across the distal end of the stricture. Then, the stent was deployed under continuous fluoroscopic control. For the Wave covered stent group, the stent was repositioned after deployment using the lasso under fluoroscopic guidance (if necessary), aligning the central portion of the stricture with the central portion of the stent which had reduced radial force and indentation. Stent positioning was confirmed endoscopically and fluoroscopically.
Sponsors & Collaborators
-
Samsung Medical Center
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 20 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-07-31
- Primary Completion
- 2014-12-31
- Completion
- 2014-12-31
Countries
- South Korea
Study Locations
More Related Trials
-
Efficacy of Partial Covered Double Bare Metal Stent Compared to Uncovered Double Bare Metal Stent in Malignant Biliary Obstruction
NCT02937246 ·Status: UNKNOWN ·Phase: NA
-
ComVi and D-type Stent in Malignant GOO
NCT01839292 ·Status: COMPLETED ·Phase: NA
-
Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi
NCT01041612 ·Status: COMPLETED ·Phase: PHASE4
-
Covered Metallic Stent and Benign Colonic Strictures
NCT01570114 ·Status: COMPLETED
-
Metal Versus Plastic Stent in Malignant Hilar Biliary Obstruction
NCT03857958 ·Status: UNKNOWN ·Phase: NA
-
EUS-GE vs ES for Palliation of Gastric Outlet Obstruction
NCT03259763 ·Status: COMPLETED ·Phase: NA
-
Uncovered Self-expandable Metal Stent Versus Double Layer Plastic Stent for Malignant Hilar Stricture
NCT01125865 ·Status: UNKNOWN ·Phase: PHASE4
-
Partially Covered and Uncovered Metal Stent for Malignant Distal Biliary Stricture
NCT02178618 ·Status: COMPLETED ·Phase: NA
-
Fully Covered or Partially Covered Stents in Malignant Esophageal Strictures
NCT01661686 ·Status: COMPLETED ·Phase: NA
-
Comparison of Duodenal Stenting vs Transpyloric and Duodenal Stenting for Malignant Obstruction
NCT03125148 ·Status: COMPLETED ·Phase: NA
-
A Prospective Randomized Study for Efficacy of Uncovered Double Bare Metallic Stent Compared to Uncovered Single Bare Metallic Stent in Malignant Biliary Obstruction
NCT01869894 ·Status: COMPLETED ·Phase: NA
-
Two-in-one Covered and Uncovered Metal Stent
NCT04337333 ·Status: UNKNOWN ·Phase: NA
-
Fully Covered SEMS Versus Partially Covered SEMS With Anti-migration System for Malignant Distal Biliary Obstruction
NCT02255669 ·Status: UNKNOWN ·Phase: NA
-
Partially Covered Metal Stents Efficacy in Biliary Drainage of Malignant Extra-hepatic Biliary Obstruction
NCT04431427 ·Status: UNKNOWN ·Phase: NA
-
Single Versus Multiple Deployment of Metallic Stents for Inoperable Malignant Hilar Biliary Obstruction
NCT02166970 ·Status: COMPLETED ·Phase: NA
-
Covered vs. Uncovered SEMS for Occluded Biliary Metal Stents
NCT01315522 ·Status: COMPLETED ·Phase: PHASE4
-
Endoscopic Stenting of Gastrointestinal Cancer
NCT00422409 ·Status: COMPLETED ·Phase: NA
-
Covered Self-expandable Metallic Stents Insertion Using Clips and Suture Materials for Preventing Migration
NCT02193789 ·Status: COMPLETED ·Phase: NA
-
Efficacy and Safety of a Fully Covered Self-Expandable Metal Stent for Unresectable HCC
NCT05729867 ·Status: UNKNOWN ·Phase: NA
-
Partially Covered Versus Uncovered Pyloro-duodenal Stents for Unresectable Malignant Gastric Outlet Obstruction. A Double Blinded Randomised Controlled Trial.
NCT03223831 ·Status: COMPLETED ·Phase: PHASE3
-
A Prospective Randomized Multi-center Study for Efficacy of Metallic Biliary Stent Compared to Plastic Stent in Patients Receiving Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer
NCT04911647 ·Status: UNKNOWN ·Phase: NA
-
Radiation Stent Versus Self-expanding Metallic Stents (SEMS) for Palliative Treatment of Malignant Biliary Stricture
NCT01320241 ·Status: COMPLETED ·Phase: PHASE2
-
Comparison Between Transpapillary and Suprapapillary Metal Stent
NCT04503291 ·Status: UNKNOWN ·Phase: NA
-
Two Bilateral Metal Stenting in Hilar Malignancy
NCT01141088 ·Status: UNKNOWN ·Phase: NA
-
Endoscopic Treatment of Biliary Stricture Caused by Chronic Pancreatitis
NCT01085747 ·Status: UNKNOWN